FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
复制标题
DOI：
10.1182/blood-2006-04-015826
复制
发表时间：
2007-08-15
期刊：
影响因子：
20.3
通讯作者：
Gale, Rosemary E.
中科院分区：
文献类型：
--
作者：
Mead, Adam J.;Linch, David C.;Gale, Rosemary E.
fms样酪氨酸激酶-3 （FLT3）基因的酪氨酸激酶结构域（TKD）突变对急性髓性白血病（AML）的预后影响目前尚不确定。为了解决这个问题，我们筛选了1107名已知FLT3内部串联重复（ITD）状态的年轻成人非急性早幼粒细胞白血病AML患者进行FLT3/ tkd检测；在127例（11%）病例中检测到它们。突变与白细胞计数高（P = 0.006）和inv患者（P = 0.005）相关，但在不良细胞遗传学和继发性AML患者中并不常见。FLT3/TKD突变型和野生型患者的5年总生存率（OS）分别为53%和37%（优势比0.72；95%可信区间0.58 ~ 0.89;P = 0.002）。对于累积复发率和OS， FLT3/TKDs和FLT3/TKDs之间的结果差异非常显著(P
The prognostic impact of tyrosine kinase domain (TKD) mutations of the fms-like tyrosine kinase-3 (FLT3) gene in acute myeloid leukemia (AML) is currently uncertain. To resolve this issue we screened 1107 young adult nonacute promyelocytic leukemia AML patients with known FLT3 internal tandem duplication (ITD) status for FLT3/TKDs; they were detected in 127 (11%) cases. Mutations were associated with a high white cell count (P =.006) and patients with inv(1 6) (P =.005) but were infrequent in patients with adverse cytogenetics and secondary AML. Overall survival (OS) at 5 years was 53% and 37% for FLT3/TKD mutant and wild-type patients respectively (odds ratio, 0.72; 95% confidence interval, 0.58 to 0.89; P =.002). For both the cumulative incidence of relapse and OS the difference in outcome between and FLT3/TKDs was highly significant (P